Previous 10 | Next 10 |
Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL PR Newswire Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-A...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Gainers: Protalix BioTherapeutics (PLX) +74%. Aterian (ATER) +62%. Dingdong Limited (DDL) +40%. Jumia Technologies (JMIA) +30%. Twitter (TWTR) +27%. Takung Art (TKAT) +24%. Gracell Biotechnologies (GRCL) +22%. Cognition Therapeutics (CGTX) +21%. Poema Global Holdings (PPGH) +20%. Biophytis (B...
Protalix BioTherapeutics (PLX) +48% as PRX–102 for Fabry disease equals Sanofi's Fabrazyme in trial. SPI Energy (SPI) +28%. Twitter (TWTR) +20% Trump SPAC Digital World sinks on report two Truth Social executives left, Musk takes Twitter stake. Red Cat Holdings (OTC...
PALO ALTO, Calif. and SUZHOU, China, March 29, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the t...
Gainers: JX Luxventure Limited (LLL) +43%. Alpha Tau Medical (DRTS) +37%. Takung Art (TKAT) +31%. Emclaire Financial (EMCF) +32%. BiondVax (BVXV) +30%. Mercurity Fintech Holding (MFH) +26%. INmune Bio (INMB) +19%. Gracell (GRCL) +21%. Aptevo (APVO) +21%. Lilium (LILM) +20%. LiqTech Internatio...
Despite recent regulatory hurdles, the U.S.-listed Chinese pharmaceutical companies have made a comeback in the morning hours on Wednesday. Notable gainers include I-Mab (IMAB +17.9%), BeiGene (BGNE +20.8%), Legend Biotech (LEGN +9.3%), Zai Lab (ZLAB +30.4%), HUTCHMED < > Limited (HCM...
Gracell Biotechnologies, Inc. (GRCL) Q4 2021 Results Conference Call March 14, 2022 08:00 AM ET Company Participants Dr. William Cao - Founder, Chairman, and Chief Executive Officer Dr. Martina Sersch - Chief Medical Officer Kevin Xie - Chief Financial Officer Conference Call Participants Joe...
The following slide deck was published by Gracell Biotechnologies Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Gracell Biotechnologies Inc. 2021 Q4 - Results - Earnings Call Presentation
Gracell Biotechnologies press release (NASDAQ:GRCL): Q4 GAAP EPS of -$0.06 beats by $0.10. As of December 31, 2021, the Company had RMB1,832.6 million (US$287.6 million) in cash and cash equivalents and short-term investments. For further details see: Gracell Biotechnologies GAAP EPS of...
News, Short Squeeze, Breakout and More Instantly...
Gracell Biotechnologies Inc. Company Name:
GRCL Stock Symbol:
NASDAQ Market:
Gracell Biotechnologies Inc. Website:
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell ...
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.49% on the day to $10.19. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of ...